Management of hepatocellular carcinoma development by Trianthema portulacastrum extract; in-vitro evidence
Said, W., A. Khattab, A., H. Aly, S., Khalil, H., A. Abo-Elmaaty, S. (2022). Management of hepatocellular carcinoma development by Trianthema portulacastrum extract; in-vitro evidence. EKB Journal Management System, 7(12), 133-136. doi: 10.21608/bjas.2022.332226
Walid Said; Abeer A. Khattab; Saadia H. Aly; Hany Khalil; Sabah A. Abo-Elmaaty. "Management of hepatocellular carcinoma development by Trianthema portulacastrum extract; in-vitro evidence". EKB Journal Management System, 7, 12, 2022, 133-136. doi: 10.21608/bjas.2022.332226
Said, W., A. Khattab, A., H. Aly, S., Khalil, H., A. Abo-Elmaaty, S. (2022). 'Management of hepatocellular carcinoma development by Trianthema portulacastrum extract; in-vitro evidence', EKB Journal Management System, 7(12), pp. 133-136. doi: 10.21608/bjas.2022.332226
Said, W., A. Khattab, A., H. Aly, S., Khalil, H., A. Abo-Elmaaty, S. Management of hepatocellular carcinoma development by Trianthema portulacastrum extract; in-vitro evidence. EKB Journal Management System, 2022; 7(12): 133-136. doi: 10.21608/bjas.2022.332226

Management of hepatocellular carcinoma development by Trianthema portulacastrum extract; in-vitro evidence

Benha Journal of Applied Sciences
Article 14, Volume 7, Issue 12, December 2022, Page 133-136  XML PDF (239.5 K)
Document Type: Original Research Papers
DOI: 10.21608/bjas.2022.332226
View on SCiNiTO View on SCiNiTO
Authors
Walid Said1; Abeer A. Khattab1; Saadia H. Aly1; Hany Khalil2; Sabah A. Abo-Elmaaty1
1Botany and Microbiology Department, Faculty of Science, Benha University, Egypt.
2Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute Sadat University, Egypt
Abstract
Liver cancer remains a worldwide concern, with more than 1 million new cases expected by 2025. Hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer, making up around 80% to 90% of all primary liver cancers, whereas the other categories include cholangiocarcinoma (10-20%) and angiosarcoma (1%). Herbal treasure contains a number of novel phytochemicals that can be employed both therapeutically and preventively to address a variety of liver-related abnormalities, including HCC. Aim: To look into the prospective activity of Trianthema portulacastrum as a folkloric plant against HCC. Methods and materials: The extract of T. portulacastrum was prepared using dimethyl sulfoxide (DMSO). The cytotoxic activity of T. portulacastrum DMSO extract on HepG2 cell lines was affirmed using the MTT assay when compared to normal cells. It was trialled in-vitro for HCC activity against MEK-1 using quantitative real-time polymerase chain reaction (qRT-PCR). Results: It showed promising inhibitory activity against MEK-1 gene expression without any detectable cytotoxic effects. It significantly blocked the Ras/Raf/MEK/ERK tumor proliferation signaling pathway and induced an apoptotic signaling pathway. Conclusion: The T. portulacastrum DMSO extract inhibited the HepG2 cells proliferation and showed anticancer activity against HCC.
Keywords
Hepatocellular carcinoma; cytotoxic activity; Ras/Raf/MEK/ERK signaling pathway; Trianthema portulacastrum
Statistics
Article View: 33
PDF Download: 56